For instance, in the presence of LPS that stimulates an acute inflammatory reaction, bromelain has decreases the elevation of This work is licensed under Creative Commons Attribution 4.0 License ANN.MS.ID.000638.
Introduction
Bromelain has been shown to demonstrate many potentially beneficial properties, both in-vitro and in-vivo, including those which are anti-oedematous, anti-thrombotic, fibrinolytic and profoundly anti-inflammatory. Clinical trials of bromelain have shown its effectiveness for treating various inflammation-based conditions. These include breast engorgement during lactation [1] , osteoarthritis of the knee and hip [2, 3] , rhinosinusitis [4] , sepsis in children [5] , and urogenital inflammation [6] . There is experimental evidence to suggest that its effects on blood coagulation is promising, where increased serum fibrinolytic activity and prostaglandin levels have been noted when the levels of PGE2 and thromboxane A2 decreased, and this finding is crucial for the lowering of inflammation [7] . Bromelain has also demonstrated an ability to inhibit bacterial endotoxin LPS-induced NF-kB activity and the expression of PGE2 and Cox-2 [8, 9] . To explain this mechanism, it was hypothesized that bromelain induces the cleavage of cell surface markers such as CD14 [10] . Among the secreted regulators of inflammation that are connected to the NF-kB pathways and that respond to bromelain are IFN-γ, TNF-α, IL-1β, and IL-6. Depending on the context and micro-environment, these regulators can either stimulate tumour growth and invasion or activate immune responses and cause tumour regression [11] [12] [13] .
The experimental evidence derived from an analysis of peripheral blood mononuclear cells (PBMC) from healthy volunteers as well as mouse macrophages suggests that bromelain can activate TNF-α, IL-1β, and IL-6 secretions in an IFN-γ-dependent mechanism [14, 15] . IFN-γ production, in turn, also increased in the presence of bromelain [16] . This data gave rise to the hypothesis that bromelain has the potential to activate a healthy immune system to ensure a rapid response to pathogens and cellular stress.
However, in situations where the immune cells have already been stimulated, bromelain reduces the secretion of TNF-α and IL-6 [17] . Chobotova et al. (2010) [18] summarized that the role of bromelain in the regulation of inflammation in a cancer network occurs when there is an over-production of cytokines induced by inflammation.
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TNF-α, IL-1β and IL-6 expressions in human PBMC. Reductions in TNF-α and IFN-γ expressions have also been observed in bromelaintreated inflamed tissues obtained from patients with inflammatory bowel disease (IBD) [19] . The described data demonstrate that the effects of bromelain on cytokine expressions depend on the presence of inflammation-inducing conditions. This underlines the potential of bromelain for the treatment of inflammation-based pathologies. However, the challenge that researchers are facing in terms of a transdermal therapeutic system (TTS) is the stratum corneum. The stratum corneum (SC) has been shown to be the main barrier to the transportation of nutritional compounds via the skin [20] . The delivery and release of bioactive materials like bromelain to different parts of the human body are practically carried out by nanocarriers. Several types of nanocarrier systems are available for transdermal drug delivery such as vesicular phospholipid gels (VPG) [21] , microspheres [22] , nanospheres [23] , nanoliposomes [24] liposomes [25] archaeosomes [26] , complexes [27] , ethosomes [28] , dendrimers [29] nanoemulsions [30] , and niosomes [31] .
The effectiveness of the delivery of bromelain to the affected sites depends on the delivery system used in the topical formulation [32] . Niosomes have specific characteristics for topical delivery and their technological and physicochemical characteristics have motivated researchers to consider them as ideal for the carriage of drugs for topical administration [33] . LPS can be a suitable agent for the simulation of inflammation conditions since it has been used to induce in-vitro and in-vivo inflammation [34] . To detect the LPSinduced inflammation, two cytokines, IL-6 and TNF-α, were selected in this study. IL-6 and TNF-α are immuno-modulating agents that act as regulators of host responses to infection, immune responses, inflammation, and trauma. They include various groups of soluble proteins, peptides, or glycoproteins which act as hormonal regulators or signalling molecules from nanomolar to picomolar concentrations [35] . Some of them are pro-inflammatory, and this is necessary to initiate the inflammatory response required for the recruitment of granulocytes and then, lymphocytes, to fight disease.
Excessive inflammation, however, is sometimes the pathogenicity of certain diseases. Other cytokines are anti-inflammatory and serve to reduce inflammation and promote healing [36] . When inflammation occurs, the cells remain alive up to a certain point but will die afterwards. In this study, niosome-encapsulated bromelain was used as an effective compound for the reduction of IL-6 and TNF-α level in LPS-induced inflammation in the skin around the knees of mice. In order to determine the effectiveness of the treatment in mice, the LPS-induced inflammation was treated with niosome-encapsulated bromelain after 4 hours of induction.
The inflammation response was measured at 4 hours. This study showed that niosome-encapsulated bromelain is effective in reducing inflammation after 4hours of post treatment.
Materials and Methods

Chemicals and mice
All the chemicals used in this study were purchased from Sigma Aldrich and Merck, unless otherwise noted. The Span (40, 60, 80), Labrasol, dicetyl phosphate, and chloroform used were also purchased from Sigma Aldrich. Bromelain was purchased from Merck, while the LPS from Escherichia coli (0111:B4) was purchased from Sigma Aldrich. The TNF-α kit (Catalogue Number RAB0476) and the IL-6 kit (Catalogue Number RAB0307) were purchased from Sigma Aldrich (USA). The analytical grade chemicals used in this study were purchased from Sigma Aldrich.
The mice were purchased from Universiti Kebangsaan Malaysia.
Preparation of niosome-encapsulated 10% bromelain(W/W)
The niosome was created based on the protocol of Arora and and humidity (50±5%) environment for a week before use.
Inflammation induction of mice with serial dilutions of LPS
The serial dilutions of LPS were modified from the protocol of Freshney (2008) [38] . After mixing 1mg of LPS with 1 mL of deionized water (DIW) according to the manufacturer's instructions (stock LPS solution), serial dilutions of the LPS were performed from 12 μg/mL to 1.5μg/mL (1.5 μg/mL, 3 μg/mL, 4.5 μg/mL, 6 μg/ mL, 7.5 μg/mL, 9 μg/mL, 10.5 μg/mL, and 12 μg/mL) by diluting the solution in an appropriate volume of deionized water. Then, the stabilized mice were given intra-articular injections of different concentrations of LPS (1.5, 3, 4.5, 6, 7.5, 9, 10.5, 12 μg/ml) into the skin area. Deionized water was used as a blank, while plasma Page 3 of 3 without LPS induction was used as the control. After 4 hours, the blood was taken and the plasma was analysed for theIL-6 and TNF-α response. Three groups of mice were prepared for the next experiment.
IL-6 and TNF-α measurements
The IL-6 and TNF-α measurements were modified from the protocol of the manufacturer's instructions. After bringing all the reagents and samples to room temperature (18-25 °C) , 100 ml of a standard and sample (0.24-0.28mL) were added into appropriate wells, which were then covered and incubated for 2.5 hours at room temperature with gentle shaking. Then, the solution was discarded and washed 4 times with wash solution (filling each well with 300 ml of a wash buffer using a multichannel pipette). After the final washing, the plate was inverted against clean paper towels. 100 mL of biotinylated antibody continued to be added to each well, which was then incubated for 1 hour at room temperature with gentle shaking. Then, the solution was discarded and the wash was repeated as before. This was followed by the addition of 100 mL of prepared streptavidin solution to each well, which was then incubated for 45 minutes at room temperature with gentle shaking.
Once again, the wells were washed and 100 mL of TMB One-Step substrate reagent was added to each well and incubated for 30 minutes at room temperature in the dark with gentle shaking.
Finally, 50 mL of the stop solution was added to each well and was read at 450 nm immediately using a UV-based micro plate reader known as the BIO-TEK, Model ELx808.
Niosome-encapsulated bromelain treatment
Prior to the experimental work, the selected mice were stabilized for one week. Their weight and body temperature were 
No
Samples Control(mL) Base Cream(g) Bromelain(mg) Niosome(mg) NSAIDS(mg) LPS(µg/mL) Vehicle(mg)
1
Optimization of niosome treatment time
The selected mice were stabilized for one week. Their weight and body temperature were recorded. Four groups containing 4 mice each were prepared for stabilization. 0.24-0.28mL of plasma was extracted from the veins of all the experimental mice as a control. After 4 hours, 7.5μg/mL LPSwas injected into all the mice, except for those in the control group. In continue, after 4 hours of LPS induction, blood was extracted from all the mice.
After 4 hours of rest, all the respective groups were treated with niosome-encapsulated bromelain. Then, blood was extracted every 15 minutes after treatment for 120 minutes. All the blood samples were refrigerated overnight prior to analysis.
Results and Discussion
Selection of suitable concentration of LPS to induce inflammation in mice
This experiment was carried out to evaluate the appropriate concentration of LPS to induce inflammation based on the response of IL-6 and TNF-α. Based on the in-vitro study, LPS concentrations of 7.5μg/mL and 9μg/mL were selected for the inflammation induction (Figure 1 & 2) . Figure 1 shows the response of IL-6 to different LPS concentrations. The response to 7.5 μg/mL LPS was 6656 pg/mL of IL-6, and to 9 μg/mL LPS, it was 7384 pg/mL of IL-6. Figure 2 shows the response of TNF-α against the LPS concentration. The Previous studies have shown that an infusion of 9 μg/mL LPS (E. coli 0114) in mice produces, on average, 7510 pg/mL of IL-1 and 5980 pg/mL of TNF-α [39] . Therefore, 7.5μg/mL LPS was selected for further experimentation.
Determination of suitable response time for niosomeencapsulated bromelain to reduce inflammation
This experiment was carried out to determine the time taken for the elimination of inflammation treated by niosome-encapsulated 10% bromelain through the responses of IL-6 and TNF-α. In this regard, the concentrations of IL-6 and TNF-α were measured for 15 minutes for a duration of 120 minutes (Table 2 and Figure 3 ). The concentration of IL-6 increased with time after treatment with niosome-encapsulated 10% bromelain. However, the best consumption time with the niosome-encapsulated 10% bromelain for IL-6 was after 30 minutes (Table 3 and Figure 4 ). 
Determination of the effectiveness of niosomeencapsulated bromelain on LPS-induced inflammation
This study was carried out to assess the effectiveness of niosome-encapsulated 10% bromelain in treating inflammation in the skin around the knees of mice when induced by 7.5μg/ mLLPS. In this regard, treatments with niosome-encapsulated 10% bromelain, bromelain alone, base cream, and hydrocortisone as anon-steroidal anti-inflammatory drug (NSAID) were performed ( Figure 5 ). Figure 6 shows the TNFα response against the treatments with niosome-encapsulated 10% bromelain, without bromelain (vehicle), and bromelain alone. The responses were 2197 pg/ mL, 5216 pg/mL, and 3286 pg/mL, respectively. The response of hydrocortisone was 2655 pg/mL, which was better than that of bromelain. The results showed that niosome-encapsulated 10% bromelain is the best treatment for LPS-induced inflammation, and it is even better than hydrocortisone, a well-known antiinflammatory drug. On the other hand, the experimental effect of niosome alone suggested that the anti-inflammatory properties of bromelain were not dependent on the presence of the vehicle [40] . [44] . Other pro-inflammatory mediators including chemokines (MIP-2), plasma enzyme mediators, and lipid mediators (COX, PG, and platelet activating factors) may be affected rather than cytokines [45, 46] .This mice model is identical to other studies of LPS and thrombotic disease [47] , atherosclerosis [48] , and cell kinetics [49] . A similar pattern was observed with antiinflammatory cytokines and chemokines, i.e., it peaked at 4 hours [50] . Generally, the results of this study showed that the treatments tested could inhibit the inflammatory cytokine responses. However, only a cell type had been used in the culture studies, whereas many cell types are capable of producing anti-inflammatory cytokines in animals. Additionally, other inflammatory mediators may influence the cytokine response.Additional key factors that should be considered are the metabolism and the distribution of the constituent compounds. In summary, this work described the novel action of niosome-encapsulated 10% bromelain in stimulating an innate anti-inflammatory response.
Statistical Analysis
In this experiment, two pairs of samples were compared using the t-Test because these two groups contributed a pair of scores.
This statistical technique is often called a paired sample t-test or correlated t-test which tells whether there is a statistically significant difference in the mean scores for niosome-encapsulated bromelain and other treatments. When P<0.05, it means that there is a significant difference.
Conclusion
This study was carried out with the aim of assessing the importance of niosome-encapsulated bromelain in the elimination of inflammation in the skin around the knees of mice infected by LPS-induced inflammation. The result showed that niosomeencapsulated 10%bromelain significantly reduced the levels of IL-6
and TNF-α in LPS-induced inflammation in mice after 4hours post treatment as compared to non-encapsulated bromelain and the vehicle.
